Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 30;134(2):145-9.
doi: 10.1016/j.imlet.2010.10.008. Epub 2010 Oct 15.

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010

Gilbert C Faure  1 , Sophie Amsellem, Christine Arnoulet, Valérie Bardet, Lydia Campos, Marcelo De Carvalho-Bittencourt, Adrienne de Labarthe, Alice Eischen, Jean Feuillard, Chantal Fossat, Francine Garnache Ottou, Estelle Guérin, Julien Guy, Hélène Jouault, Emilienne Kuhlein, Francis Lacombe, Elodie Lainey, Marc Maynadié, Maria Elena Noguera, Mikael Roussel, Françoise Solly, Orianne Wagner Ballon, Marie C Béné; GEIL workshop
Affiliations

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010

Gilbert C Faure et al. Immunol Lett. .

Abstract

The B-cell panel of the ninth HLDA was applied in a multicentre fashion to cryopreserved cells from 46 patients with acute lymphoblastic leukemia. The reagents were aliquoted and shipped to volunteer participants from the French Groupe d'Etude Immunologique des Leucémies (GEIL). All samples were tested in flow cytometry, and the results collected as of the strength of labeling of the leukemic clone as negative, weak or strong. Among the 64 antibodies tested, the strongest and most frequent staining was observed for CD305 (LAIR), CD229 (Ly9), CD200 (OX-2) and, to a lesser extent, CD361 (EVI2b). Details of the observations, and information about the molecules tested are provided in the manuscript as well as a summary table.

PubMed Disclaimer

Publication types

LinkOut - more resources